diallylguanidin | 42072-35-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: diallylguanidin
• 英文别名: 1,1-Diallyl-guanidin；n,n-Diallyl-guanidine；1,1-bis(prop-2-enyl)guanidine
• CAS: 42072-35-5
• 化学式: C₇H₁₃N₃
• mdl: MFCD19206573
• 分子量: 139.2
• InChiKey: IKLZKOIQPGTTFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  diallylguanidin acetate 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 13.5h， 以100%的产率得到diallylguanidin
  参考文献：
  名称：

  Macromolecular design of new cationic polyelectrolytes

  摘要：

  Methods were elaborated for the synthesis of new monomers, derivatives of diallylguanidine and macromers, which contain fragments of polytetrahydrofuran and diallylic nitrogen-containing end groups (diallylamine, alkyldiallylammonium, diallylguanidine both in base and acetate forms). Alkylation of a macromer with a diallylamine end group was carried out with methyl iodide in various organic solvents. The possibility of synthesis of diallylguanidine acetate homopolymer as well as its statistical copolymer with diallyldimethylammonium chloride was shown. For the first time, block copolymers based on synthesized macromers were obtained.

  DOI：

  10.1007/bf00696318

文献信息

• Tetrahydroquinazoline Derivatives Useful as Anticancer Agents
  申请人：PFIZER INC.

  公开号：US20190248767A1

  公开（公告）日：2019-08-15

  Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  具有一般公式： 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。
• Pyrimidine derivatives as corticotropin releasing factor inhibitors
  申请人：——

  公开号：US20040229891A1

  公开（公告）日：2004-11-18

  The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) 1 useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.

  本发明涉及公式（I）的新型杂环拮抗剂，以及包含所述拮抗剂的催乳素释放因子受体（“CRF受体”）的药物组合物，用于治疗抑郁症、焦虑症、情感障碍、进食障碍、创伤后应激障碍、头痛、药物成瘾、炎症性疾病、药物或酒精戒断症状以及其他可以通过CRF-1受体拮抗来治疗的疾病。
• Novel chain-breaking antioxidants
  申请人：——

  公开号：US20020143025A1

  公开（公告）日：2002-10-03

  Compounds, preferably 5-pyrimidinol and 3-pyridinol derivatives, that act as effective chain breaking antioxidants of both the lipid and water-soluble variety (analogous to the natural Vitamins E and C), many of which are more reactive toward peroxyl radicals than the most potent form of Vitamin E. These compounds may exhibit many chemopreventive effects associated with conditions in which free radical-mediated cellular damage or disruption is implicated and Vitamins E and C are shown to have protective effects. Additionally, these compounds should be excellent oxidation inhibitors as additives to fuels, lubricants, rubber, polymers, chemicals, solvents and foodstuffs.

  化合物，最好是5-嘧啶醇和3-吡啶醇衍生物，作为有效的链断裂抗氧化剂，既可以溶解于脂质又可以溶解于水（类似于天然维生素E和C），其中许多对过氧自由基的反应性比最有效的维生素E形式更高。这些化合物可能展现出许多与自由基介导的细胞损伤或破坏相关的化学预防效应，而维生素E和C已经显示出具有保护作用。此外，这些化合物应该作为添加剂，对燃料、润滑剂、橡胶、聚合物、化学品、溶剂和食品等具有出色的氧化抑制作用。
• Remedies for inflammatory bowel diseases
  申请人：——

  公开号：US20030212115A1

  公开（公告）日：2003-11-13

  Prophylactic and/or therapeutic drugs against ulcerative colitis, which include five-member heterocyclic compounds represented by the formula (I) or these nontoxic salts as active principle, 1 (wherein Z represents the group containing &agr;-aminocarbonyl group, R 1 represents (1) substituted alkyl, alkenyl or alkynyl groups, (2) OH, (3) amino, (4) alkylamino, (5) dialkylamino, etc., X and Y represent oxygen atom, sulfur atom or substituted nitrogen atom.)

  预防和/或治疗溃疡性结肠炎的药物，包括由式(I)表示的五元杂环化合物或这些无毒盐作为活性成分，其中Z代表含有α-氨基羰基的基团，R1代表(1)取代烷基、烯基或炔基基团，(2) OH，(3) 氨基，(4) 烷基氨基，(5) 二烷基氨基等，X和Y代表氧原子、硫原子或取代的氮原子。
• Airway mucus secretion inhibitors
  申请人：——

  公开号：US20030216324A1

  公开（公告）日：2003-11-20

  Prophylactic and/or therapeutic drugs against diseases with the augmentative airway mucus secretion, which include five-member heterocyclic compounds represented by the formula (I) or these nontoxic salts as active principle, 1 (wherein Z represents the group containing &agr;-aminocarbonyl group, R 1 represents (1) substituted alkyl, alkenyl or alkynyl groups, (2)OH, (3)amino, (4)alkylamino, (5)dialkylamino, etc., X and Y represent oxygen atom, sulfur atom or substituted nitrogen atom.)

  预防和/或治疗增多的气道粘液分泌疾病的药物，包括由式(I)所代表的五元杂环化合物或这些无毒盐作为活性原理，其中Z代表含有α-氨基羰基的基团，R1代表(1)取代烷基、烯基或炔基基团，(2) OH，(3) 氨基，(4) 烷基氨基，(5) 二烷基氨基等，X和Y代表氧原子、硫原子或取代的氮原子。